New HRD test uses SOPHiA DDM™ Platform to increase accuracy in HRD detection
BOSTON and Rolle, Switzerland, July 19, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Taiwanese genomics lab SOFIVA GENOMICS has introduced a new product using SOPHiA GENETICS technology. The product is a new homologous recombination deficiency (HRD) test – the SOFIVA GENOMICS HRD Status Test – that leverages the SOPHiA DDM™ Platform to increase accuracy in HRD detection.
HRD is caused by a cell’s impaired ability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway and is linked with the development of certain cancers, including advanced ovarian cancer, which is one of the top 10 causes of death for women in Taiwan. For those diagnosed with ovarian cancer, HRD has been shown to be a potential predictive biomarker for therapy response.
SOFIVA GENOMICS has long been devoted to the research and development of cancer-based precision medicine and the SOFIVA GENOMICS HRD Test is its latest breakthrough. With the SOPHiA DDM™ Platform, the SOFIVA GENOMICS HRD Test is expected to provide a fast and highly accurate assessment of HRD-positive tumors, helping to support decision-making.
“Our collaboration with SOPHiA Genetics is deeply advantageous for refining and localizing precision medicine in Taiwan. SOPHiA GENETICS provides a framework for localizing HRD testing in Taiwan, allowing us to retain genetic data needed to perfect the robustness and accuracy of HRD testing services and help even more patients identify suitable treatment,” shares SOFIVA GENOMICS’ general manager, Chia-Cheng Hung.
Testing for HRD can produce a complex data set that is time-intensive and costly to analyze. The SOPHiA DDM™ Platform uses artificial intelligence and machine learning with patented technologies to analyze raw next-generation sequencing (NGS) data, streamlining it for simplified interpretation, and expedited reporting.
“The SOFIVA GENOMICS HRD Test uses the strengths of the SOPHiA DDM™ Platform to provide highly accurate testing that aids clinical researchers in making data-driven decisions,” said Ricardo Mendonca Filho, PhD, Managing Director, LAPAC, SOPHiA GENETICS. “We are proud to work with SOFIVA GENOMICS and support their efforts to advance precision medicine in their market, making it more accessible to their population.”
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
